Literature DB >> 23643756

Assessment of subjective cognitive and emotional effects of antipsychotic drugs. Effect by defect?

Steffen Moritz1, Christina Andreou, Stefan Klingberg, Teresa Thoering, Maarten J V Peters.   

Abstract

Antipsychotic medication represents the first-line treatment for schizophrenia. While it is undisputed that antipsychotics ameliorate positive symptoms, the exact cognitive and emotional pathways through which the effect is exerted has remained unclear. The present study investigated the subjective effects of antipsychotics across various domains of cognition and emotion in both patients with psychotic symptoms and patients with other psychiatric diagnoses. A total of 69 patients with a probable history of psychosis or psychotic symptoms and 26 patients with psychiatric diagnoses other than psychosis participated in a survey conducted over the Internet. Multiple control measures aimed to secure response validity. All patients were currently or had previously been treated with antipsychotic agents. A questionnaire comprising 49 items and measuring possible effects of antipsychotics on cognition and emotion was administered. For 30 out of 49 items a clear response pattern emerged, which was similar for patients with psychotic disorders and patients with other diagnoses. Factor analysis of these items revealed three main effects of antipsychotic medication related to doubt and self-doubt, cognitive and emotional numbing, and social withdrawal. Antipsychotic treatment appears to be connected to a number of negative subjective effects on cognition and emotion. Further studies are warranted to assess how these effects impact on the patients' subjective well-being and quality of life, as well as their association with antipsychotic efficacy on one hand, and adherence rates on the other. Induction of doubt and dampening of emotion may be one reason why antipsychotics work and at the same time offer an explanation why they are experienced as rather unpleasant and are eventually discontinued by many patients.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23643756     DOI: 10.1016/j.neuropharm.2013.04.039

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  13 in total

1.  A novel aminotetralin-type serotonin (5-HT) 2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses.

Authors:  Clinton E Canal; Drake Morgan; Daniel Felsing; Krishnakanth Kondabolu; Neil E Rowland; Kimberly L Robertson; Rajeev Sakhuja; Raymond G Booth
Journal:  J Pharmacol Exp Ther       Date:  2014-02-21       Impact factor: 4.030

Review 2.  Classics in Chemical Neuroscience: Aripiprazole.

Authors:  Austen B Casey; Clinton E Canal
Journal:  ACS Chem Neurosci       Date:  2017-04-13       Impact factor: 4.418

3.  Effects of β-Arrestin-Biased Dopamine D2 Receptor Ligands on Schizophrenia-Like Behavior in Hypoglutamatergic Mice.

Authors:  Su M Park; Meng Chen; Claire M Schmerberg; Russell S Dulman; Ramona M Rodriguiz; Marc G Caron; Jian Jin; William C Wetsel
Journal:  Neuropsychopharmacology       Date:  2015-07-01       Impact factor: 7.853

4.  Self-reported affective traits and current affective experiences of biological relatives of people with schizophrenia.

Authors:  Anna R Docherty; Scott R Sponheim; John G Kerns
Journal:  Schizophr Res       Date:  2014-11-29       Impact factor: 4.939

5.  Influence of aripiprazole, risperidone, and amisulpride on sensory and sensorimotor gating in healthy 'low and high gating' humans and relation to psychometry.

Authors:  Philipp A Csomor; Katrin H Preller; Mark A Geyer; Erich Studerus; Theodor Huber; Franz X Vollenweider
Journal:  Neuropsychopharmacology       Date:  2014-05-07       Impact factor: 7.853

6.  Associations between visual perception accuracy and confidence in a dopaminergic manipulation study.

Authors:  Christina Andreou; Vasilis P Bozikas; Thies Luedtke; Steffen Moritz
Journal:  Front Psychol       Date:  2015-04-16

7.  Targeted training modifies oscillatory brain activity in schizophrenia patients.

Authors:  Tzvetan G Popov; Almut Carolus; David Schubring; Petia Popova; Gregory A Miller; Brigitte S Rockstroh
Journal:  Neuroimage Clin       Date:  2015-03-20       Impact factor: 4.881

8.  Negative evaluation bias for positive self-referential information in borderline personality disorder.

Authors:  Dorina Winter; Cornelia Herbert; Katrin Koplin; Christian Schmahl; Martin Bohus; Stefanie Lis
Journal:  PLoS One       Date:  2015-01-22       Impact factor: 3.240

9.  Metacognition-augmented cognitive remediation training reduces jumping to conclusions and overconfidence but not neurocognitive deficits in psychosis.

Authors:  Steffen Moritz; Teresa Thoering; Simone Kühn; Bastian Willenborg; Stefan Westermann; Matthias Nagel
Journal:  Front Psychol       Date:  2015-08-03

10.  Are negative symptoms in schizophrenia a distinct therapeutic target?

Authors:  Octavia Oana Capatina; Ioana Valentina Miclutia
Journal:  Clujul Med       Date:  2018-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.